John B. Buse

1 month ago | ajmc.com | Giuliana Grossi |Christian C. Ruff |John B. Buse |Marc P. Bonaca |Marc Humbert |Jawad Haider Butt | +1 more

At the American College of Cardiology Annual Scientific Session (ACC.25), experts shared groundbreaking research poised to reshape cardiovascular care—particularly for women and patients with complex cardiometabolic conditions.

1 month ago | pharmacytimes.com | Alexandra Gerlach |John B. Buse

At the American College of Cardiology 2025 Scientific Sessions, John Buse, MD, PhD, professor of medicine at the University of North Carolina Chapel Hill, discussed the latest findings on GLP-1 receptor agonists and their role in cardiovascular risk reduction. He highlighted key trials, including the LEADER trial (NCT01179048) with liraglutide (Victoza; Novo Nordisk) and recent studies on semaglutide, emphasizing the consistency of cardiovascular benefits across different formulations.

1 month ago | ajmc.com | Giuliana Grossi |John B. Buse

New data presented at the American College of Cardiology 2025 Annual Scientific Session found that patients with type 2 diabetes taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely to experience cardiovascular death, heart attack, or stroke over an average follow-up of 4 years compared with placebo.

Aug 12, 2024 | healio.com | Michael Monostra |Richard Smith |John B. Buse |Athena Philis-Tsimikas

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The percentage of adults with hypercortisolism and difficult-to-control type 2 diabetes was higher than researchers expected.

Jun 24, 2024 | healio.com | Michael Monostra |Richard Smith |John B. Buse |Athena Philis-Tsimikas

Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The percentage of adults with hypercortisolism and difficult-to-control type 2 diabetes was higher than researchers expected.